Clinical Trial Update: A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating CICS-1 and SPM-011 for unresectable angiosarcoma, sponsored by Stella Pharma, is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma

Drugs mentioned

• CICS-1
• SPM-011

Snippet

Sponsor: Stella Pharma Corporation | Conditions: Unresectable Angiosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING